The Roadmap Series

The HIV Drug Pipeline and its Patents

The HIV Drug Pipeline and its Patents: August 2013

In August 2013, the Initiative for Medicines, Access & Knowledge (I-MAK) created The Roadmap: The HIV Drug Pipeline and its Patents, the first report to showcase clinical, cost, and legal/patent information on important HIV antiretroviral (ARV) medicines in the pipeline. It aimed to help expand access to the next generation of lifesaving ARVs in multiple ways. Using The Roadmap, advocates can decide which medicines need short- or long-term attention and make informed decisions about the best strategies to pursue, such as patent oppositions, compulsory licenses (CL), voluntary license (VL) negotiations, and/or direct advocacy.

Download the Report

The Roadmap Special Edition Report on Dolutegravir: June 2017

In order to provide key information updates for prioritized ARVs, I-MAK created The Roadmap Special Edition Report on Dolutegravir (DTG). This report expands on the information provided in the original Roadmap to equip stakeholders with current clinical, cost, and patent information to inform decision-making about the best strategies to expand currently limited access to DTG, a second-generation, best in class HIV integrase strand transfer inhibitor that greatly improves upon drugs in its class and is highly suitable for large treatment programs in low- and middle-income countries.

Download the Report

Join us to stay updated
and help make lifesaving medicines accessible to all